Disease · MONDO_0005377

nephrotic syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nephrotic syndrome. Diseases, record MONDO_0005377. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005377

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nephrotic syndrome; Open Targets
Open Targets ID: MONDO_0005377; Open Targets
Other names: nephrotic syndrome (acquired), nephrotic syndromes, syndrome, nephrotic, syndromes, nephrotic; Open Targets
Disease Ontology: DOID:1184; Disease Ontology
MeSH: D009404; MeSH
NCI Thesaurus: C34845; NCI Thesaurus
Highest stage of its drugs: Approval, for 19 of its 50 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	114	5	4	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	21	5	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
FUROSEMIDE	CHEMBL35	Small molecule	Approval	DailyMed	52	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	3	1	0	Drugs and targets
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	DailyMed	102	0	0	Drugs and targets
BUMETANIDE	CHEMBL1072	Small molecule	Approval	DailyMed and FDA	23	0	0	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Approval	DailyMed and EMA Human Drugs	8	0	0	Drugs and targets
CHLOROTHIAZIDE	CHEMBL842	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	13	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
SLC12A1	Solute carrier family 12 member 1	3	Sodium-(potassium)-chloride cotransporter 2 inhibitor	Approval	https://conductscience.org/library/genes/6557	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	3	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Approval	https://conductscience.org/library/genes/6559	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	2	Lymphocyte differentiation antigen CD38 inhibitor	Phase 2	https://conductscience.org/library/genes/952	Drugs and targets
F10	Coagulation factor X	2	Coagulation factor X inhibitor	Phase 1/2	https://conductscience.org/library/genes/2159	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3615	Drugs and targets
SCNN1A	Amiloride-sensitive sodium channel, ENaC	2	Amiloride-sensitive sodium channel, ENaC blocker	Approval	https://conductscience.org/library/genes/6337	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials53

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02132195	Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome	Phase 3	31	2019-05-10	Nephrotic Syndrome	CORTICOTROPIN	Its record names the disease	ClinicalTrials.gov
NCT05079789	Amiloride in Nephrotic Syndrome	Phase 3	20	2025-01-14	Nephrotic Syndrome, Edema, Sodium Retention	AMILORIDE, FUROSEMIDE	Its record names the disease	ClinicalTrials.gov
NCT01113385	Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome	Not applicable	7	2014-09-15	Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome	GALACTOSE	Its record names the disease	ClinicalTrials.gov
NCT03703908	A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome	Phase 2	5	2024-02-06	Focal Segmental Glomerulosclerosis	ILACIRNON	Its record names the disease	ClinicalTrials.gov
NCT02390362	Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome	Phase 3	3	2019-03-26	Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome	MYCOPHENOLATE MOFETIL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02257697	A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome	Phase 3	239		Nephrotic Syndrome	CYCLOPHOSPHAMIDE, MIZORIBINE	Its record names the disease	ClinicalTrials.gov
NCT04045171	Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome		200		Nephrotic Syndrome, Tacrolimus, Pharmacokinetics	TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04585152	Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.	Phase 2	160		Nephrotic Syndrome Steroid-Dependent	MYCOPHENOLATE MOFETIL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT07320612	Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome	Phase 1	160		Nephrotic Syndrome	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT06079788	Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.	Phase 3	140		Nephrotic Syndrome in Children	CORTICOTROPIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 53

See all 53 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Amiloride vs Furosemide: deaths from any cause	0 of 10	0 of 10	20	NCT05079789	Trial comparisons
Amiloride vs Furosemide: serious adverse events	1 of 10	4 of 10	20	NCT05079789	Trial comparisons
Rituximab vs Mycophenolate Mofetil (MMF): deaths from any cause	0 of 1	0 of 2	3	NCT02390362	Trial comparisons
Rituximab vs Mycophenolate Mofetil (MMF): serious adverse events	0 of 1	0 of 2	3	NCT02390362	Trial comparisons

Papers from its trials25

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42027554	RESULT	1	PubMed
36223961	RESULT	2	PubMed
34884411	RESULT	1	PubMed
41448676	DERIVED	1	PubMed
41333097	DERIVED	1	PubMed
40993587	DERIVED	1	PubMed
40478760	DERIVED	1	PubMed
40337980	DERIVED	2	PubMed
40180405	DERIVED	1	PubMed
39513526	DERIVED	10	PubMed

1 to 10 of 25

See all 25 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005377

GET https://conductscience.org/api/diseases/v1/MONDO_0005377/drugs?page=2

API reference For AI assistants